About vTv Therapeutics (NASDAQ:VTVT)
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:VTVT
- CUSIP: N/A
- Web: vtvtherapeutics.com/
- Market Cap: $71.53 million
- Outstanding Shares: 9,693,000
- 50 Day Moving Avg: $6.30
- 200 Day Moving Avg: $6.30
- 52 Week Range: $3.57 - $8.09
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.28
- P/E Growth: 0.00
- Annual Revenue: $119,000.00
- Price / Sales: 601.13
- Book Value: ($10.98) per share
- Price / Book: -0.67
- EBITDA: ($52,990,000.00)
- Net Margins: -103,184.60%
- Return on Assets: -127.94%
- Current Ratio: 2.95%
- Quick Ratio: 2.95%
- Average Volume: 38,733 shs.
- Beta: 0.9
- Short Ratio: 9.39
Frequently Asked Questions for vTv Therapeutics (NASDAQ:VTVT)
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. View vTv Therapeutics' Earnings History.
When will vTv Therapeutics make its next earnings announcement?
Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?
4 brokerages have issued twelve-month price objectives for vTv Therapeutics' shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' share price to reach $16.50 in the next twelve months. View Analyst Ratings for vTv Therapeutics.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Cempra (CEMP), Summit Therapeutics PLC (SMMT), Immune Design Corp. (IMDZ), Cellular Biomedicine Group (CBMG), Cidara Therapeutics (CDTX), Verona Pharma Plc (VRP), DURECT (DRRX), MaxCyte (MXCT), ImmuPharma PLC (IMM), Synthetic Biologics (SYN), Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Intec Pharma (NTEC), Summit Therapeutics PLC (SUMM), Motif Bio PLC (MTFB), Otonomy (OTIC), ProQR Therapeutics N.V. (PRQR) and MEI Pharma (MEIP).
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Jeffrey B. Kindler, Executive Chairman of the Board
- Stephen L. Holcombe, President, Chief Executive Officer
- Rudy C. Howard CPA, Chief Financial Officer, Executive Vice President
- Larry Douglas Altstiel M.D. Ph.D., Chief Medical Officer
- Steven M. Cohen, Director
- Paul M. Meister, Director
- Paul G. Savas, Director
- Howard L. Weiner, Director
- John A. Fry, Independent Director
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Who owns vTv Therapeutics stock?
vTv Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
MACANDREWS & FORBES INC.
(78.10%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
How do I buy vTv Therapeutics stock?
Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of vTv Therapeutics stock can currently be purchased for approximately $7.38.
Earnings History for vTv Therapeutics (NASDAQ:VTVT)Earnings History by Quarter for vTv Therapeutics (NASDAQ VTVT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.43)||($0.41)||$0.19 million||$0.01 million||View||N/A|
|5/3/2017||Q1 2017||($0.44)||($0.44)||$0.20 million||$0.03 million||View||N/A|
|3/1/2016||Q4||($0.47)||($0.35)||$0.03 million||$0.23 million||View||N/A|
Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS
Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.80%Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership Percentage: 11.05%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/22/2017||Ronald O Perelman||Major Shareholder||Buy||20,000||$4.57||$91,400.00|| |
|8/16/2017||Ronald O Perelman||Major Shareholder||Buy||10,000||$4.97||$49,700.00|| |
|8/15/2017||Ronald O Perelman||Major Shareholder||Buy||50,000||$4.72||$236,000.00|| |
|8/11/2017||Ronald O Perelman||Major Shareholder||Buy||85,000||$4.13||$351,050.00|| |
|5/15/2017||Paul G Savas||Director||Buy||3,000||$5.18||$15,540.00|| |
|3/31/2017||Paul G Savas||Director||Buy||10,000||$6.50||$65,000.00|| |
|5/27/2016||Paul G Savas||Director||Buy||6,000||$5.67||$34,020.00|| |
|5/24/2016||Paul G Savas||Director||Buy||1,259||$5.26||$6,622.34|| |
|4/8/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$4.99||$49,900.00|| |
|4/5/2016||Ronald O Perelman||Major Shareholder||Buy||400,000||$5.20||$2,080,000.00|| |
|3/28/2016||Paul G Savas||Director||Buy||10,000||$5.35||$53,500.00|| |
|3/24/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$5.64||$56,400.00|| |
|3/7/2016||Paul G Savas||Director||Buy||15,000||$5.82||$87,300.00|| |
|2/12/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$5.83||$58,300.00|| |
|2/5/2016||Ronald O Perelman||Major Shareholder||Buy||10,000||$6.43||$64,300.00|| |
|2/4/2016||Ronald O Perelman||Major Shareholder||Buy||20,000||$6.05||$121,000.00|| |
|1/13/2016||Ronald O Perelman||Major Shareholder||Buy||15,000||$6.41||$96,150.00|| |
|12/18/2015||Ronald O Perelman||Major Shareholder||Buy||15,000||$6.40||$96,000.00|| |
|12/15/2015||Noel Joseph Spiegel||Director||Buy||5,710||$6.20||$35,402.00|| |
|10/2/2015||Ronald O Perelman||Major Shareholder||Buy||30,000||$6.26||$187,800.00|| |
|9/28/2015||Ronald O Perelman||Major Shareholder||Buy||40,000||$6.04||$241,600.00|| |
|9/25/2015||Paul G Savas||Director||Buy||5,000||$6.62||$33,100.00|| |
|9/22/2015||Ronald O Perelman||Major Shareholder||Buy||24,000||$6.82||$163,680.00|| |
Headline Trends for vTv Therapeutics (NASDAQ:VTVT)
Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
Loading headlines, please wait.
vTv Therapeutics (VTVT) Chart for Monday, October, 23, 2017